Now showing items 1-12 of 12

    • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints 

      Koyama, Shohei; Akbay, Esra A.; Li, Yvonne Y.; Herter-Sprie, Grit S.; Buczkowski, Kevin A.; Richards, William G.; Gandhi, Leena; Redig, Amanda J.; Rodig, Scott J.; Asahina, Hajime; Jones, Robert E.; Kulkarni, Meghana M.; Kuraguchi, Mari; Palakurthi, Sangeetha; Fecci, Peter E.; Johnson, Bruce E.; Janne, Pasi A.; Engelman, Jeffrey A.; Gangadharan, Sidharta P.; Costa, Daniel B.; Freeman, Gordon J.; Bueno, Raphael; Hodi, F. Stephen; Dranoff, Glenn; Wong, Kwok-Kin; Hammerman, Peter S. (Nature Publishing Group, 2016)
      Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. ...
    • Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth 

      Nemeth, Zsuzsanna; Csizmadia, Eva; Vikstrom, Lisa; Li, Mailin; Bisht, Kavita; Feizi, Alborz; Otterbein, Sherrie; Zuckerbraun, Brian; Costa, Daniel B.; Pandolfi, Pier Paolo; Fillinger, Janos; Döme, Balazs; Otterbein, Leo E.; Wegiel, Barbara (Impact Journals LLC, 2016)
      We hypothesized that tumor-associated macrophages (TAMs) are controlled by the diffusible gas carbon monoxide (CO). We demonstrate that induction of apoptosis in lung tumors treated with low doses of CO is associated with ...
    • BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations 

      Costa, Daniel Botelho; Halmos, Balázs; Kumar, Amit; Schumer, Susan T; Huberman, Mark Stephen; Boggon, Titus J; Tenen, Daniel Geoffrey; Kobayashi, Susumu (Public Library of Science, 2007)
      Background: Epidermal growth factor receptor (EGFR) mutations are present in the majority of patients with non-small cell lung cancer (NSCLC) responsive to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. ...
    • Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers 

      Rangachari, Deepa; Yamaguchi, Norihiro; Vanderlaan, Paul A; Folch, Erik E; Mahadevan, Anand; Floyd, Scott R.; Uhlmann, Erik J; Wong, Eric S.; Dahlberg, Suzanne Eleanor; Huberman, Mark S.; Costa, Daniel Botelho (Elsevier BV, 2015)
      Introduction—Brain metastases (BM) are common in non-small-cell lung cancer (NSCLC). However, the baseline incidence and evolution of BM over time in oncogene-driven NSCLCs are seldom reported. In this study, we evaluated ...
    • CCAAT/Enhancer Binding Protein β Is Dispensable for Development of Lung Adenocarcinoma 

      Cai, Yi; Hirata, Ayako; Nakayama, Sohei; VanderLaan, Paul A.; Levantini, Elena; Yamamoto, Mihoko; Hirai, Hideyo; Wong, Kwok-Kin; Costa, Daniel B.; Watanabe, Hideo; Kobayashi, Susumu S. (Public Library of Science, 2015)
      Lung cancer is the leading cause of cancer death worldwide. Although disruption of normal proliferation and differentiation is a vital component of tumorigenesis, the mechanisms of this process in lung cancer are still ...
    • Experience with targeted next generation sequencing for the care of lung cancer: Insights into promises and limitations of genomic oncology in day-to-day practice 

      Rangachari, Deepa; Vanderlaan, Paul A; Le, Xiuning; Folch, Erik E; Kent, Michael; Gangadharan, Sidhu; Majid, Adnan; Haspel, Richard Lawrence; Joseph, Loren Jay; Huberman, Mark S.; Costa, Daniel Botelho (Elsevier BV, 2015)
      Introduction Tumor genotyping using single gene assays (SGAs) is standard practice in advanced non-small-cell lung cancer (NSCLC). We evaluated how the introduction of next generation sequencing (NGS) into day-to-day ...
    • In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer 

      Hirano, Toshiyuki; Yasuda, Hiroyuki; Tani, Tetsuo; Hamamoto, Junko; Oashi, Ayano; Ishioka, Kota; Arai, Daisuke; Nukaga, Shigenari; Miyawaki, Masayoshi; Kawada, Ichiro; Naoki, Katsuhiko; Costa, Daniel B.; Kobayashi, Susumu S.; Betsuyaku, Tomoko; Soejima, Kenzo (Impact Journals LLC, 2015)
      EGFR mutated lung cancer accounts for a significant subgroup of non-small-cell lung cancer (NSCLC). Over the last decade, multiple EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been developed to target mutated EGFR. ...
    • De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors 

      Le, Xiuning; DeSai, Neelam V.; Majid, Adnan; Karp, Rebecca Sara; Huberman, Mark S.; Rangachari, Deepa; Kent, Michael; Gangadharan, Sidhu; Folch, Erik E; Vanderlaan, Paul A; Costa, Daniel Botelho (Elsevier BV, 2015)
      Introduction Epidermal growth factor receptor (EGFR) mutations are present in 10-20% of all non-small-cell lung cancers and predict for response to EGFR tyrosine kinase inhibitors (TKIs). However, the incidence of these ...
    • Rapidly fatal advanced EGFR -mutated lung cancers and the need for rapid tumor genotyping in clinical practice 

      Rangachari, Deepa; Drake, Lauren; Huberman, Mark S.; McDonald, Danielle C.; Vanderlaan, Paul A; Folch, Erik E; Costa, Daniel Botelho (Elsevier BV, 2016)
      Use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is associated with dramatic, durable, and tolerable responses and side effect profiles, respectively, when applied for palliation of advanced ...
    • RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer 

      Niederst, Matthew J.; Sequist, Lecia V.; Poirier, John T.; Mermel, Craig H.; Lockerman, Elizabeth L.; Garcia, Angel R.; Katayama, Ryohei; Costa, Carlotta; Ross, Kenneth N.; Moran, Teresa; Howe, Emily; Fulton, Linnea E.; Mulvey, Hillary E.; Bernardo, Lindsay A.; Mohamoud, Farhiya; Miyoshi, Norikatsu; VanderLaan, Paul A.; Costa, Daniel B.; Jänne, Pasi A.; Borger, Darrell R.; Ramaswamy, Sridhar; Shioda, Toshi; Iafrate, Anthony J.; Getz, Gad; Rudin, Charles M.; Mino-Kenudson, Mari; Engelman, Jeffrey A. (Nature Pub. Group, 2015)
      Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous ...
    • Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice 

      Yamaguchi, Norihiro; Vanderlaan, Paul A; Folch, Erik E; Boucher, David H.; Canepa, Hannah M.; Kent, Michael; Gangadharan, Sidhu; Majid, Adnan; Kocher, Olivier Nicolas; Goldstein, Michael A.; Huberman, Mark S.; Costa, Daniel Botelho (Elsevier BV, 2013)
      Introduction The identification of somatic genomic aberrations in non-small-cell lung cancer (NSCLC) is part of evidence-based practice guidelines for care of patients with NSCLC. We sought to establish the frequency and ...
    • Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer 

      Vanderlaan, Paul A; Yamaguchi, Norihiro; Folch, Erik E; Boucher, David H.; Kent, Michael; Gangadharan, Sidhu; Majid, Adnan; Goldstein, Michael A.; Huberman, Mark S.; Kocher, Olivier Nicolas; Costa, Daniel Botelho (Elsevier BV, 2014)
      Introduction—Identification of some somatic molecular alterations in non-small-cell lung cancer (NSCLC) has become evidence-based practice. The success and failure rate of using commercially-available tumor genotyping ...